BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
31 results:

  • 1. High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
    Brzezinska B; Mysona DP; Richardson KP; Rungruang B; Hopkins D; Bearden G; Higgins R; Johnson M; Satter KB; McIndoe R; Ghamande S; Purohit S
    Gynecol Oncol; 2023 Dec; 179():1-8. PubMed ID: 37862814
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Mechanism of Marsdenia tenacissima against ovarian cancer based on network pharmacology and experimental verification].
    Hu YJ; Wei LY; Zhao J; Zhu QF; Meng ZY; Meng JJ; Chen JJ; Xu LY; Zhou YY; Han YL
    Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2222-2232. PubMed ID: 37282910
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
    Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M;
    Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Total tumor diameter is a better indicator of multifocal papillary thyroid microcarcinoma: A propensity score matching analysis.
    Jiang KC; Lin B; Zhang Y; Zhao LQ; Luo DC
    Front Endocrinol (Lausanne); 2022; 13():974755. PubMed ID: 36004348
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Plant Alkaloid Tetrandrine Is a Nuclear Receptor 4A1 Antagonist and Inhibits Panc-1 Cell Growth In Vitro and In Vivo.
    Lee HS; Kim DH; Lee IS; Park JH; Martin G; Safe S; Kim KJ; Kim JH; Jang BI; Lee SO
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563670
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Molecular mechanism of Spatholobi Caulis in treatment of ovarian cancer based on network pharmacology and experimental verification].
    Zhu SC; Cai J; Wu CY; Cheng CS
    Zhongguo Zhong Yao Za Zhi; 2022 Feb; 47(3):786-795. PubMed ID: 35178962
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinicopathological characteristics, prognostic factors and treatment outcomes of seminomatous germ cell tumours from a tertiary cancer centre in eastern India.
    Dabkara D; Ganguly S; Ghosh J; Mukherjee S; Gupta S; Mallick I; Mukherjee S; Midha D; Chatterjee M; Basu A; Hasan A; Biswas B
    Natl Med J India; 2021; 34(2):68-72. PubMed ID: 34599114
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
    Hegde A; Andreev-Drakhlin AY; Roszik J; Huang L; Liu S; Hess K; Cabanillas M; Hu MI; Busaidy NL; Sherman SI; Dadu R; Grubbs EG; Ali SM; Lee J; Elamin YY; Simon GR; Blumenschein GR; Papadimitrakopoulou VA; Hong D; Meric-Bernstam F; Heymach J; Subbiah V
    ESMO Open; 2020 Oct; 5(5):e000799. PubMed ID: 33097651
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid cancer: Results of a Randomized, Multicenter Phase II Trial.
    Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
    Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
    [No Abstract]    [Full Text] [Related]  

  • 10. A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer.
    Beachler DC; Lamy FX; Russo L; Taylor DH; Dinh J; Yin R; Jamal-Allial A; Dychter S; Lanes S; Verpillat P
    J Ovarian Res; 2020 Aug; 13(1):101. PubMed ID: 32867806
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.
    Assis J; Pereira C; Nogueira A; Pereira D; Carreira R; Medeiros R
    Cancer Treat Rev; 2017 Dec; 61():35-52. PubMed ID: 29100168
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Total tumour diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis.
    Liu C; Wang S; Zeng W; Guo Y; Liu Z; Huang T
    Sci Rep; 2017 May; 7(1):1846. PubMed ID: 28500312
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
    Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
    Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish ttd Collaborative Group.
    Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
    Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities.
    Li L; Bai H; Yang J; Cao D; Shen K
    Oncotarget; 2017 Feb; 8(9):15136-15148. PubMed ID: 28122348
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ercc2.
    Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
    Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Evaluation of laparoscopic transperitoneal adrenalectomy: is it feasible for large masses?
    Mesci A; Celik O; Akand M; Aydogdu O; Arici G; Arici C; Erdogru T
    Minerva Urol Nefrol; 2015 Sep; 67(3):175-8. PubMed ID: 25877815
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. ttd consensus document on the diagnosis and management of exocrine pancreatic cancer.
    Benavides M; Abad A; Ales I; Carrato A; Díaz Rubio E; Gallego J; García-Foncillas J; Grávalos C; Laquente B; Pericay C; Rivera F; Tabernero J; Aranda E
    Clin Transl Oncol; 2014 Oct; 16(10):865-78. PubMed ID: 24728654
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.
    Peters GJ; Avan A; Ruiz MG; Orsini V; Avan A; Giovannetti E; Smit EF
    Anticancer Res; 2014 Jan; 34(1):435-42. PubMed ID: 24403499
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
    Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
    Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.